Monday, 2 December 2013

PharmaPoint: Pediatric Respiratory Syncytial Virus (RSV) Prophylactics - US Drug Forecast and Market Analysis to 2022

Reportstack has announced a new market report on PharmaPoint: Pediatric Respiratory Syncytial Virus (RSV) Prophylactics - US Drug Forecast and Market Analysis to 2022. Respiratory syncytial virus (RSV) is a common cause of pediatric respiratory infections and virtually all children will have been infected by the virus by the age of two. RSV transmission typically occurs during the winter and early spring months. The virus is spread through the air by an infected person’s sneeze or cough, or through direct and indirect contact with nasal secretions of an infected person. The majority of RSV infections present as mild upper respiratory illnesses that often self-resolve within two weeks, but about 1% of the cases develop serious lower respiratory complications requiring hospitalization. Children under the age of two with certain health conditions are most at risk for severe RSV infections and are therefore recommended to receive RSV prophylaxis treatments. The only FDA-approved prophylactic intervention in the US is AstraZeneca’s Synagis (palivizumab), a humanized monoclonal antibody against the fusion protein of the virus.

Scope
Overview of RSV, including epidemiology, etiology, general symptoms from infection, and US prophylaxis guidelines comparison (American Academy of Pediatrics vs National Perinatal Association).
Annualized RSV market revenue, annual cost of therapy and utilization pattern data from 2012 and forecast for ten years to 2022.
Key topics covered include strategic competitor assessment, market characterization, unmet needs and remaining opportunities, clinical trial overview and implications for the RSV market.
Pipeline analysis: analysis of two pipeline vaccines and potential market and clinical position in the RSV market.
Analysis of the current and future RSV market. Insightful review of the key industry and governmental drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Market Model Features
An interactive excel forecast model based on primary research interviews and surveys with KOLs and high-prescribing physicians is included in this report*. This patient based model provides diagnosis rates, patient segmentation, treatment rates, annual costs of therapy , and indication-specific drug sales for the 10 year forecast period. The forecast model is robust, fully transparent, and easy to navigate. Moreover, our models support data presented in the reports and the complete methodology is outlined in the report and the model.

*Model only available with site and global license purchases.

Key Findings
The majority of physicians adhere to the AAP guidelines limiting the number of doses and narrowing the use of Synagis
AstraZeneca, with Synagis, will continue its stronghold of the RSV market for the forecast period
Pipeline prophylactic indications will be first in class (active/maternal immunization), and will cover complementary populations.

To view the table of contents and know more details please visit PharmaPoint: Pediatric Respiratory Syncytial Virus (RSV) Prophylactics - US Drug Forecast and Market Analysis to 2022 report.

MediPoint: Peripheral Vascular Stents for the Lower Extremity - Global Analysis and Market Forecasts

Reportstack has announced a new market report on MediPoint: Peripheral Vascular Stents for the Lower Extremity - Global Analysis and Market Forecasts. Endovascular therapies such as stenting have been widely adopted to treat peripheral artery disease in the lower extremity. Peripheral vascular stents including bare metal, drug-eluting, covered and bioabsorbable stents are associated with improved clinical outcomes compared to balloon angioplasty alone. The global peripheral vascular stent (PVS) market is steadily growing in the 10 countries covered in the report, including the US, France, Germany, Italy, Spain, UK, Japan, Brazil, China and India.

It is evident that currently the peripheral vascular stent market for the lower extremity is saturated with bare metal stents, followed by covered stents. However, as clinical data and appropriate reimbursement and costs are established, adoption of innovative stent technologies such as drug-eluting stents and bioabsorbable stents will increase in the future.

By the end of the forecast period, the competitive landscape will experience significant change due to the launch of bioabsorbable stents in the market, the expansion of approved indications to include infrapopliteal artery lesions and the entry of new companies such as 480 Biomedical. Regions Covered: US, France, Germany, Italy, Spain, UK, Japan, Brazil, China and India.

Market Model Features
An interactive excel forecast model based on primary research interviews and surveys with KOLs, physicians, industry participants and distributors is included in this report*. The forecast model is robust, fully transparent, and easy to navigate. Moreover, our models support data presented in the reports and the complete methodology is outlined in the report and the model.
*Interactive excel forecast model only available to clients purchasing a site license or higher.

“What Physicians Think” quotes provide a unique insight into how healthcare professionals are reacting to events within the industry, and what their responses could mean for industry strategists. This information is essential for all strategic decision makers in every organization allowing them to act on high quality information.

To view the table of contents and know more details please visit MediPoint: Peripheral Vascular Stents for the Lower Extremity - Global Analysis and Market Forecasts report.

PharmaFocus: Biomarkers in Alzheimer's Disease

Reportstack has announced a new market report on PharmaFocus: Biomarkers in Alzheimer's Disease. Alzheimer’s disease (AD) is a progressive neurodegenerative disease that is characterized by memory loss, cognitive impairment, and functional decline. The disease has emerged as a major global health priority especially because of its rapidly accelerating prevalence worldwide. In order to tackle the AD scourge , there is an urgent need for tools that will allow for the early and accurate diagnosis of AD, as well as the identification of populations at risk. A biomarker is an indicator of biological processes that can be objectively measured and evaluated, and well-validated biomarkers are required to satisfy these needs in AD.
The search for biomarkers that are reflective of the disease process in AD has been and continues to be an active area of research, but has been hampered by a lack of clear understanding of the pathological mechanisms that underlie the disease. Nonetheless, several biomarkers have been developed to date that indicate the presence of AD pathology and AD-associated neuronal injury in vivo. Such biomarkers have the potential for clinical use in etiological determination, predictive prognosis, monitoring disease progression, and in clinical trials of potential disease-modifying therapies for AD .

Scope
Overview of Alzheimer's disease, including disease etiology and pathophysiology and how these inform biomarker targets.
Overview of AD biomarkers, the major classes of biomarkers an the different potential roles of biomarkers in clinical use and drug development.
Key topics covered include amyloid biomarkers, tau biomarkers, and other molecular biomarkers for AD in development with product profiles for marketed as well as promising pipeline assays. Also discussed are functional and structural imaging biomarkers for AD.
Analysis of the unmet needs, and opportunities within the AD biomarker arena, as well as drivers and barriers impacting the AD biomarker market . Insightful review of the regulatory considerations impacting biomarker development, market access and use in clinical drug development

Reasons To Buy
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the factors shaping and driving AD biomarker development and market adoption.
Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the AD biomarker market in future.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

To view the table of contents and know more details please visit PharmaFocus: Biomarkers in Alzheimer's Disease report

PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Analysis to 2022

Reportstack has announced a new market report on PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Analysis to 2022. The Dry Eye Syndrome (DES) pipeline is strong, with 49 molecules in various phases of development. More notably, the late-stage pipeline has three products with novel mechanisms of action to treat the inflammation associated with the disease. That said, physicians suggest that the largest unmet need for DES treatment is diagnosis.

Scope
Annualized market revenues data for 9 key markets: US, France, Germany, Italy, Spain, UK, Japan, China, and India
Annualized market revenues data from 2012 to 2022 and forecast from 2012 to 2022
Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by the 9 key markets. Pipeline candidates fall under major therapeutic classes
Analysis of key recent licensing and partnership agreements in the DES Therapeutics market
Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications
Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications.
Market Model Features
An interactive excel forecast model based on primary research interviews and surveys with KOLs and high-prescribing physicians is included in this report*. This patient based model provides diagnosis rates, patient segmentation, treatment rates, annual costs of therapy , and indication-specific drug sales for the 10 year forecast period. The forecast model is robust, fully transparent, and easy to navigate. Moreover, our models support data presented in the reports and the complete methodology is outlined in the report and the model.

*Model only available with site and global license purchases.

Key Findings
The global DES therapeutics market is forecast to reach $5.47 billion by 2022 due to the launch of novel pipeline drugs and an aging population.
The global push for increased physician and patient awareness will increase diagnosis and treatment.
By 2022, the DES market will be significantly more competitive, but the current dearth of treatment options leave much room for the coming pipeline therapies.

To view the table of contents and know more details please visit PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Analysis to 2022 report.

Sunday, 1 December 2013

Europe Endoscopy Devices Market Outlook to 2019

Reportstack has announced a new market report on Europe Endoscopy Devices Market Outlook to 2019 - Capsule Endoscope Systems, Endoscopic Instruments, Flexible Endoscopes, Rigid Endoscopes and Others. provides key market data on the Europe Endoscopy Devices market – France, Germany, Italy, Spain and United Kingdom. The report provides value (USD million) data for all the market categories – Capsule Endoscope Systems, Endoscopic Instruments, Endoscopic Reprocessors, Endoscopy Fluid Management Systems, Endoscopy Visualization Systems, Flexible Endoscopes and Rigid Endoscopes. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by team of industry experts.

Scope

- Countries covered include France, Germany, Italy, Spain and United Kingdom.
- Market size and company share data for Endoscopy Devices market categories – Capsule Endoscope Systems, Endoscopic Instruments, Endoscopic Reprocessors, Endoscopy Fluid Management Systems, Endoscopy Visualization Systems, Flexible Endoscopes and Rigid Endoscopes.
- Annualized market revenues (USD million) data for each of the market categories in each of the country. Data from 2005 to 2012, forecast forward for 7 years to 2019.
- 2012 company shares and distribution shares data for each of the market categories and countries.
- Global corporate-level profiles of key companies operating within the Europe Endoscopy Devices market..
- Key players covered include Olympus Corporation, Hoya Corporation, Fujifilm Holdings Corporation, KARL STORZ GmbH & Co. KG, Given Imaging Ltd., Richard Wolf GmbH and others.

Reasons to buy

- Develop business strategies by identifying the key market categories and segments poised for strong growth.
- Develop market-entry and market expansion strategies.
- Design competition strategies by identifying who-stands-where in the Europe Endoscopy Devices competitive landscape.
- Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.
- What are the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize.

The Companies Mentioned in this report includes Olympus Corporation Hoya Corporation Fujifilm Holdings Corporation KARL STORZ GmbH & Co. KG Given Imaging Ltd. Richard Wolf GmbH Stryker Corporation Advanced Sterilization Products Services Inc. Medivators Inc. Soluscope SAS B. Braun Melsungen AG Steris Corporation Getinge AB IntroMedic Co., Ltd. Custom Ultrasonics Incorporated Wassenburg Medical Devices B.V. Chongqing Jinshan Science & Technology (Group) Co., Ltd.

To view the table of contents and know more details please visit Europe Endoscopy Devices Market Outlook to 2019 - Capsule Endoscope Systems, Endoscopic Instruments, Flexible Endoscopes, Rigid Endoscopes and Others report.

MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts

Reportstack has announced a new market report on MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts. The ACS in vitro diagnostics market is dominated by a single biomarker test, cardiac troponins. However, this market remains of high interest due to advancements in assay sensitivity both on laboratory and point-of-care platforms. GlobalData expects these advancements to have an impact on other diagnostic tests such as creatine kinase-MB isoenzyme and myoglobin. Furthermore, the emergence of pipeline biomarker tests will change the landscape of ACS in vitro diagnostic testing and is expected to provide enhancements in the early diagnosis of the disease.

Acute coronary syndrome (ACS) consists of two major diseases, myocardial infarction (MI) and unstable angina, with the former being one of the major killers in the mature markets. Though the incidence of ACS is either in decline or steady across the US and European countries, millions of ACS and suspected ACS patients still visit emergency rooms every year with symptoms such as chest pain, and these patients are typically assessed with in vitro diagnostic cardiac biomarker tests. The ACS diagnostic cardiac biomarker reagents market is dominated by the cardiac troponins, the gold-standard biomarkers for the diagnosis of MI.

Scope

- An overview of ACS, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
- Annualized APAC ACS in vitro diagnostic testing reagents market revenue and future forecasts from 2009 to 2011, forecast for 7 years to 2018.
- Investigation of current and future market competition for diagnostic cardiac biomarkers for ACS
- Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events.
- Competitor assessment including device approval analysis and device sales forecasts.
- Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast.
- Analysis of unmet needs within the market and opportunities for future players.
- Technology trends evaluation to assess strength of pipeline.
- An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines.
- Company profiles including business description, financial overview and SWOT analysis.
- Coverage of key market players.
- Strategic assessment of the diagnostic cardiac biomarkers for ACS sector through market impact analysis, future market scenario and company analysis.
- Direct quotes from Key Opinion Leaders (KOL) as well as cardiologists

Reasons to buy

- Understand the trends shaping and driving APAC diagnostic cardiac biomarkers for ACS.
- Realize device preferences of physicians who have performed the tests already.
- Access market sizing, forecasts and quantified growth opportunities in APAC diagnostic cardiac biomarkers for ACS Market through 2018.
- Quantify candidate patient populations to better design product pricing & launch plans.
- Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape.
- Perform benchmarking analysis of growth opportunities against currently marketed products.
- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
- Take a comprehensive look at the market’s device pipeline and identify promising, paradigm-shifting products.
- Create an effective counter-strategy to gain a competitive advantage against those currently in the market.
- Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth.
- What’s the next big thing in APAC diagnostic cardiac biomarkers for ACS market landscape? Identify, understand and capitalize.

The Companies Mentioned in this report are Abbott Diagnostics Alere Beckman Coulter bioMérieux Mitsubishi Chemical Medience Corporation Ortho-Clinical Diagnostics Radiometer Medical Randox Laboratories Response Biomedical Roche Diagnostics Siemens Healthcare Thermo Scientific.

To view the table of contents and know more details please visit MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts report.

MediPoint: Breast Cancer Imaging - US Analysis and Market Forecasts

Reportstack has announced a new market report on MediPoint: Breast Cancer Imaging - US Analysis and Market Forecasts. Breast cancer is the most common form of cancer in women in both the developed and developing world, but is a rare disease in men. The global incidence of breast cancer is increasing due to an increased lifespan and increasing adoption of western lifestyle risk factors. Early diagnosis of breast cancer is the foundation for increasing survival rates and diagnostic imaging is the most widely used technique to achieve early detection, making diagnostic imaging a cornerstone of breast cancer control.

The US breast cancer imaging market is a mature industry with complex dynamics and it is essential to examine the market opportunities and barriers that are specific to this region. This report provides an in-depth review of the evolving technologies and the regulatory landscape of the breast cancer screening market in the US.

Scope

- An overview of breast cancer, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
- Annualized US Breast cancer imaging market revenue and future forecasts from 2009 to 2011, forecast for 7 years to 2018.
- Investigation of current and future market competition for Breast cancer imaging
- Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events.
- Competitor assessment including device approval analysis and device sales forecasts.
- Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast.
- Analysis of unmet needs within the market and opportunities for future players.
- Technology trends evaluation to assess strength of pipeline.
- An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines.
- Company profiles including business description, financial overview and SWOT analysis.
- Coverage of key market players.
- Strategic assessment of the Breast cancer imaging sector through market impact analysis, future market scenario and company analysis.
- Direct quotes from Key Opinion Leaders (KOL) as well as radiologists

Reasons to buy

- Understand the trends shaping and driving the US Breast cancer imaging Market.
- Realize device preferences of physicians who have performed the tests already.
- Access market sizing, forecasts and quantified growth opportunities in the US Breast cancer imaging Market through 2018.
- Quantify candidate patient populations to better design product pricing & launch plans.
- Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape.
- Perform benchmarking analysis of growth opportunities against currently marketed products.
- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
- Take a comprehensive look at the market’s device pipeline and identify promising, paradigm-shifting products.
- Create an effective counter-strategy to gain a competitive advantage against those currently in the market.
- Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth.
- What’s the next big thing in US Breast cancer imaging market landscape? Identify, understand and capitalize.

The Companies Mentioned in this report are GE Healthcare Hologic Siemens Koninklijke Philips Electronics Fujifilm Medical Systems Internazionale Medico Scientifica (IMS) Planmed Konica Minolta Medical Imaging Agfa Healthcare Carestream Health SonoCine Aurora Imaging Technology Imaging Diagnostic Systems Naviscan Dilon Diagnostics Gamma Medica.

To view the table of contents and know more details please visit MediPoint: Breast Cancer Imaging - US Analysis and Market Forecasts report.